Embera adds $4.5 million in Series A cash

Embera NeuroTherapeutics says it has garnered $4.5 million in a continuation of its Series A financing. The money will go to development of new treatments for smoking cessation and other addictions. "This investment will enable us to complete preclinical development for EMB-001 and to bring this drug candidate entirely through a Phase I safety study," said CEO Bob Linke. Release

Suggested Articles

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.